Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celgene Corporation

Related CELG
Celgene Receives Positive CHMP Opinion For OTEZLA, The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis
Which Mega Caps Are Buying Their Own Stock?
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $91.00 to $94.00.

Jefferies noted, “CELG announced Abraxane met its overall survival primary endpoint in its Phase 3 pancreatic cancer study. We have long considered this indication to be risky and upside to our valuation. Adding pancreatic cancer to our valuation raises our price target from $91 to $94.”

Celgene Corporation closed on Friday at $71.50.

Latest Ratings for CELG

DateFirmActionFromTo
Oct 2014CitigroupMaintainsBuy
Oct 2014Credit SuisseMaintainsOutperform
Sep 2014Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters